Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.34 USD | +0.01% | -8.84% | +32.68% |
May. 15 | Canaccord Genuity Trims Price Target on Passage Bio to $13 From $14, Maintains Buy Rating | MT |
Mar. 04 | Passage Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+32.68% | 82.56M | |
+9.05% | 114B | |
+11.41% | 104B | |
-12.43% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-2.59% | 17.89B | |
+8.14% | 14.28B | |
+35.07% | 12.55B |
- Stock Market
- Equities
- PASG Stock
- News Passage Bio, Inc.
- Transcript : Passage Bio, Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-16-2022 08